Phillips Wealth Planners LLC Purchases 203 Shares of Novo Nordisk A/S (NYSE:NVO)

Phillips Wealth Planners LLC grew its position in Novo Nordisk A/S (NYSE:NVOFree Report) by 8.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,750 shares of the company’s stock after buying an additional 203 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Novo Nordisk A/S were worth $237,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $48,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.5 %

NVO opened at $80.59 on Thursday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 0.89 and a beta of 0.45. The company’s 50 day moving average price is $96.63 and its two-hundred day moving average price is $116.04.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $140.20.

View Our Latest Stock Report on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Articles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.